health
U.S. Food And Drug Administration Awards Additional Funding For QTORINTM Rapamycin For The Treatment Of Microcystic Lymphatic Malformations
(MENAFN - GlobeNewsWire - Nasdaq) NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORINTM rapamycin has ...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Meet Jordic: The Unlikely Voice Of A Heart-Health Warning Men Need To Hear
Menafn
YR Fitness Plans To Expand One-Stop Gym Solutions With Design And Fit-Out Services
Menafn
Dr. Simon Ourian, Whose Patients Have Included Kim Kardashian And Adriana Lima, Launches 'Ask Dr. Ourian'
Menafn
Regentis Biomaterials And The Shift From Symptom Management To Structural Repair In Knee Cartilage Care
Menafn
Stucco Restoration At Hillsborough Nursing Center Brings A Beneficial Side Effect
Menafn